Interim report January – June 2021
Curasight A/S (“Curasight” or the “Company”) hereby publishes the interim report for the period January 1 – June 30, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: ”During the quarter we successfully reported positive outcome of the biodistribution study in glioblastoma with uTREAT[®], which constitutes a green light to proceed into further testing. Curasight’s uTREAT[®]-technology has previously shown promising results in completed preclinical studies